Safety Run-In Phase (Srp) Cohorts 1 And 2 Of The Immunib Trial (Aio-Hep-0218/Ass): An Open-Label, Single-Arm Phase Ii Study Evaluating Safety And Efficacy Of Immunotherapy With Pd-L1/L2 Inhibition (Nivolumab) In Combination With Receptor Tyrosine Kinase Inhibition (Lenvatinib) In Advanced Stage Hepatocellular Carcinoma (Hcc).